1. Pearson PG, Wienkers LC (2009) Handbook of drug metabolism, 2nd edn. Informa Healthcare, New York
2. Food and Drug Administration (2008) Table of valid genomic biomarkers in the context of approved drug labels. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm . Accessed Feb 2012
3. Nishihara M, Sudo M, Kawaguchi N, Takahashi J, Kiyota Y, Kondo T, Asahi S (2011) An unusual metabolic pathway of sipoglitazar, a novel anti-diabetic agent: cytochrome P450-catalyzed oxidation of sipoglitazar acyl glucuronide. Drug Metab Dispos 34:1220–1228
4. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, Smith JC, Markham AF (1989) Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 17:2503–2516
5. Guillemette C (2003) Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J 3:136–158